SHANDONG BOAN BIOTECH.H 1 (UJ9) - Total Liabilities
Based on the latest financial reports, SHANDONG BOAN BIOTECH.H 1 (UJ9) has total liabilities worth €1.39 Billion EUR (≈ $1.62 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore UJ9 net asset momentum to track the company's year-over-year net asset growth rate.
SHANDONG BOAN BIOTECH.H 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how SHANDONG BOAN BIOTECH.H 1's total liabilities have evolved over time, based on quarterly financial data.
SHANDONG BOAN BIOTECH.H 1 Competitors by Total Liabilities
The table below lists competitors of SHANDONG BOAN BIOTECH.H 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Studio City International Holdings Ltd
NYSE:MSC
|
USA | $2.16 Billion |
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
USA | $129.28 Million |
|
Lavvi Empreendimentos Imobiliários S.A
SA:LAVV3
|
Brazil | R$2.20 Billion |
|
Acacia Research Corporation
NASDAQ:ACTG
|
USA | $188.65 Million |
|
Unipar Carbocloro S.A
SA:UNIP3
|
Brazil | R$5.42 Billion |
|
Alandsbanken Abp B
HE:ALBBV
|
Finland | €4.84 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥4.31 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANDONG BOAN BIOTECH.H 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of SHANDONG BOAN BIOTECH.H 1.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANDONG BOAN BIOTECH.H 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANDONG BOAN BIOTECH.H 1 (2021–2025)
The table below shows the annual total liabilities of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.39 Billion ≈ $1.62 Billion |
+14.79% |
| 2024-12-31 | €1.21 Billion ≈ $1.41 Billion |
+20.30% |
| 2023-12-31 | €1.00 Billion ≈ $1.17 Billion |
+27.97% |
| 2022-12-31 | €784.18 Million ≈ $916.79 Million |
+41.32% |
| 2021-12-31 | €554.92 Million ≈ $648.76 Million |
-- |
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more